BioXell starts Phase II BPH study

BioXell (Milan, Italy) started a double-blind, placebo-controlled Italian Phase II study of BXL-628 in 120 patients with benign prostatic hyperplasia (BPH). BXL-628 is a vitamin D3 analog that inhibit...